TNSN08170A1 - 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors - Google Patents

3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors

Info

Publication number
TNSN08170A1
TNSN08170A1 TNP2008000170A TNSN08170A TNSN08170A1 TN SN08170 A1 TNSN08170 A1 TN SN08170A1 TN P2008000170 A TNP2008000170 A TN P2008000170A TN SN08170 A TNSN08170 A TN SN08170A TN SN08170 A1 TNSN08170 A1 TN SN08170A1
Authority
TN
Tunisia
Prior art keywords
alkyl
synthesis
renin inhibitors
tetrahydrofutran
pyrrolidin
Prior art date
Application number
TNP2008000170A
Inventor
Gottfried Sedelmeier
Dominique Grimler
Murat Acemoglu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451886&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN08170(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN08170A1 publication Critical patent/TNSN08170A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula II, or a salt thereof, and a compound of formula Vl or a salt thereof, wherein R3 and R4 as well as Act are as defined in the specification, and processes of manufacturing these. Additionally transformation of compounds (Vl) with metallo organic compounds (VII) give rise to the new compounds (VMI) which are direct precursors for the preparation of Aliskiren.
TNP2008000170A 2005-10-17 2008-04-16 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors TNSN08170A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0521083.6A GB0521083D0 (en) 2005-10-17 2005-10-17 Organic compounds
PCT/EP2006/009970 WO2007045420A2 (en) 2005-10-17 2006-10-16 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors

Publications (1)

Publication Number Publication Date
TNSN08170A1 true TNSN08170A1 (en) 2009-10-30

Family

ID=35451886

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000170A TNSN08170A1 (en) 2005-10-17 2008-04-16 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors

Country Status (30)

Country Link
US (2) US7772405B2 (en)
EP (1) EP1948643B1 (en)
JP (3) JP5356031B2 (en)
KR (1) KR101294432B1 (en)
CN (2) CN103121995B (en)
AR (1) AR058089A1 (en)
AU (1) AU2006303489B2 (en)
BR (1) BRPI0617492A2 (en)
CA (2) CA2829487A1 (en)
CY (1) CY1114308T1 (en)
DK (1) DK1948643T3 (en)
EC (1) ECSP088368A (en)
ES (1) ES2427098T3 (en)
GB (1) GB0521083D0 (en)
HK (1) HK1120509A1 (en)
HR (1) HRP20130793T1 (en)
IL (1) IL190330A (en)
JO (1) JO2926B1 (en)
MY (1) MY145466A (en)
NO (1) NO342854B1 (en)
NZ (1) NZ567042A (en)
PE (2) PE20120581A1 (en)
PL (1) PL1948643T3 (en)
PT (1) PT1948643E (en)
RU (1) RU2432354C2 (en)
SI (1) SI1948643T1 (en)
TN (1) TNSN08170A1 (en)
TW (1) TWI395733B (en)
WO (1) WO2007045420A2 (en)
ZA (1) ZA200802632B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102005052195A1 (en) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Process for the preparation of chiral octenoic acid derivatives
JP2010523523A (en) * 2007-04-03 2010-07-15 ノバルティス アーゲー New method
US20100184998A1 (en) * 2007-06-19 2010-07-22 Beatriz Dominguez Organic compounds
DE102007049039A1 (en) * 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Process for the preparation of 8-hydrazino-8-aryl-octanoyl derivatives and their use
EP2189442B1 (en) * 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
CN101774986B (en) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 Method for preparing aliskiren and intermediate thereof
CN102241650B (en) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 Intermediate compound for preparing aliskiren and related preparation method
CN102485722B (en) * 2010-12-06 2014-05-07 博瑞生物医药技术(苏州)有限公司 Aliskiren, its intermediates and medicinal salt, as well as preparation method thereof
CN102775393B (en) * 2011-05-09 2014-08-27 上海现代制药股份有限公司 Preparation method for intermediate of medicine
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN102746182B (en) * 2012-07-27 2014-09-03 浙江普洛医药科技有限公司 Preparation method of Aliskiren
CN103059012B (en) * 2013-01-30 2016-06-22 浙江海翔药业股份有限公司 1,8-dicarbapentaborane-4,5-epoxide and preparation method thereof
CN104876832B (en) * 2014-02-28 2016-12-07 华润双鹤药业股份有限公司 The 4-position epimer of aliskiren, Preparation Method And The Use
CN105294612A (en) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 Aliskiren intermediate, and preparation method therefor and application thereof
US10087190B1 (en) * 2017-04-24 2018-10-02 Purdue Research Foundation Lactones

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6777574B1 (en) 1999-07-29 2004-08-17 Speedel Pharma Ag 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production
FR2801051B1 (en) * 1999-11-17 2001-12-14 Adir NOVEL AMINOPYRROLINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6310904B1 (en) 2000-05-31 2001-10-30 Honeywell International, Inc. Measurement method to facilitate production of self-aligning laser gyroscope block
DK1215201T3 (en) 2000-12-14 2007-01-29 Speedel Pharma Ag Process for the preparation of aryloctanylamides
WO2003022811A1 (en) * 2001-09-07 2003-03-20 Basf Aktiengesellschaft Method for the production of 2-pyrrolidone
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CN102260188A (en) * 2003-11-26 2011-11-30 诺瓦提斯公司 organic compounds
TW200529845A (en) * 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
US7851634B2 (en) * 2004-03-19 2010-12-14 Novartis Ag 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
EP1582523A1 (en) * 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
GB0511686D0 (en) 2005-06-08 2005-07-13 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CY1114308T1 (en) 2016-08-31
WO2007045420A2 (en) 2007-04-26
CN103121995B (en) 2016-08-03
ECSP088368A (en) 2008-05-30
CN103121995A (en) 2013-05-29
AU2006303489B2 (en) 2011-04-07
US20100267965A1 (en) 2010-10-21
TWI395733B (en) 2013-05-11
CA2625034A1 (en) 2007-04-26
AU2006303489A1 (en) 2007-04-26
DK1948643T3 (en) 2013-09-08
TW200800965A (en) 2008-01-01
US20080262246A1 (en) 2008-10-23
PE20070792A1 (en) 2007-09-10
ES2427098T3 (en) 2013-10-28
KR101294432B1 (en) 2013-08-07
EP1948643B1 (en) 2013-06-05
HRP20130793T1 (en) 2013-09-30
HK1120509A1 (en) 2009-04-03
RU2008119276A (en) 2009-11-27
JP2009514808A (en) 2009-04-09
NO342854B1 (en) 2018-08-20
GB0521083D0 (en) 2005-11-23
CN101111493A (en) 2008-01-23
MY145466A (en) 2012-02-15
ZA200802632B (en) 2009-04-29
PT1948643E (en) 2013-09-05
JO2926B1 (en) 2015-09-15
RU2432354C2 (en) 2011-10-27
US7772405B2 (en) 2010-08-10
CA2625034C (en) 2014-08-19
KR20080057285A (en) 2008-06-24
PL1948643T3 (en) 2013-11-29
JP5792139B2 (en) 2015-10-07
US8198465B2 (en) 2012-06-12
NO20082263L (en) 2008-07-07
SI1948643T1 (en) 2013-10-30
JP2013032369A (en) 2013-02-14
IL190330A (en) 2013-12-31
EP1948643A2 (en) 2008-07-30
CA2829487A1 (en) 2007-04-26
JP5356031B2 (en) 2013-12-04
JP2014196312A (en) 2014-10-16
NZ567042A (en) 2012-02-24
WO2007045420A3 (en) 2007-06-07
CN101111493B (en) 2013-02-13
IL190330A0 (en) 2009-09-22
BRPI0617492A2 (en) 2011-07-26
AR058089A1 (en) 2008-01-23
PE20120581A1 (en) 2012-06-08

Similar Documents

Publication Publication Date Title
TNSN08170A1 (en) 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
TN2009000401A1 (en) New methods
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
WO2007091009A3 (en) Preparation of delmopinol
TW200716544A (en) Organic compounds
GB0719180D0 (en) New process
WO2008155338A3 (en) Process for the synthesis of intermediates of renin inhibitors such as aliskiren
IL174469A0 (en) Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics
TW200609215A (en) Organic compounds
SG170794A1 (en) Process for preparation of hiv protease inhibitors
WO2007126893A3 (en) A convergent process for the synthesis of taxane derivatives
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
TNSN08142A1 (en) Synthesis of renin inhibitors involving a cycloaddition reaction
WO2006136552A3 (en) Process for the production of intermadiates for the preparation of tricyclic benzimidazoles
WO2006122020A3 (en) Process for production of 4-biphenylyazetidin-2-ones
IL200323A0 (en) Synthesis of glyt-1 inhibitors
WO2007044490A3 (en) Process for making heteroaryl amine intermediate compounds
TH89325B (en) Organic compounds
WO2006133322A3 (en) Synthesis of 3-amino-4-substituted pyrazole derivatives
TH88107A (en) Organic compounds
TH88107B (en) Organic compounds
TH89325A (en) Derivatives of 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofuran-2-il) pyridin-2-transfer. (3-alkyl-5- (4-alkyl-5-oxo-tetrahydrifuran-2-yl) pyrrolidin-2-one) as a methyman in the synthesis of renin inhibitors.
TW200716559A (en) Preparation of 3-amino-4,5-disubstituted-pyrazole derivatives